U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drugs@FDA

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Biologic License Application (BLA): 761125
Company: NOVARTIS PHARMS CORP
Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
BEOVU brolucizumab-dbll 6MG/0.05ML INJECTABLE; INTRAVITREAL Prescription None No No
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
10/07/2019 ORIG-1 Approval N/A Label (PDF)
Letter (PDF)
Review
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761125Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761125_Orig1_toc.cfm
Supplements
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
09/28/2023 SUPPL-20 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761125s020lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/761125Orig1s020ltr.pdf
12/19/2022 SUPPL-17 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761125s017lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761125Orig1s017ltr.pdf
02/18/2022 SUPPL-13 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761125s010s012s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761125Orig1s010, s012, s013ltr.pdf
02/18/2022 SUPPL-12 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761125s010s012s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761125Orig1s010, s012, s013ltr.pdf
02/18/2022 SUPPL-10 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761125s010s012s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761125Orig1s010, s012, s013ltr.pdf
05/27/2022 SUPPL-8 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761125s008lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761125Orig1s008ltr.pdf
06/09/2020 SUPPL-4 Supplement Label (PDF)
Letter (PDF)
Review (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761125s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/761125Orig1s004ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761125Orig1s004.pdf
03/09/2022 SUPPL-2 Supplement

Label is not available on this site.

Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
Patient Package Insert
Note Url
09/28/2023 SUPPL-20 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761125s020lbl.pdf
12/19/2022 SUPPL-17 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761125s017lbl.pdf
05/27/2022 SUPPL-8 Efficacy-New Indication Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761125s008lbl.pdf
02/18/2022 SUPPL-13 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761125s010s012s013lbl.pdf
02/18/2022 SUPPL-12 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761125s010s012s013lbl.pdf
02/18/2022 SUPPL-10 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761125s010s012s013lbl.pdf
06/09/2020 SUPPL-4 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761125s004lbl.pdf
10/07/2019 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf
Back to Top